Peter Corry
Concepts (449)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperthermia, Induced | 24 | 2012 | 114 | 1.970 |
Why?
| | Hot Temperature | 29 | 2012 | 198 | 1.390 |
Why?
| | Heat-Shock Proteins | 11 | 2005 | 103 | 1.160 |
Why?
| | Radiotherapy, Intensity-Modulated | 10 | 2017 | 184 | 1.120 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 12 | 2017 | 262 | 0.960 |
Why?
| | Antioxidants | 2 | 2020 | 256 | 0.880 |
Why?
| | Radiometry | 8 | 2017 | 127 | 0.820 |
Why?
| | Neoplasms | 19 | 2016 | 1300 | 0.760 |
Why?
| | Tomography, Spiral Computed | 5 | 2017 | 56 | 0.700 |
Why?
| | Radiation-Protective Agents | 3 | 2020 | 72 | 0.690 |
Why?
| | Abdomen | 2 | 2011 | 75 | 0.680 |
Why?
| | Heart | 4 | 2013 | 345 | 0.600 |
Why?
| | Radiotherapy | 4 | 2014 | 127 | 0.600 |
Why?
| | Oxygen | 3 | 2012 | 332 | 0.590 |
Why?
| | Radiotherapy, Image-Guided | 3 | 2016 | 25 | 0.560 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 177 | 0.540 |
Why?
| | Radiation Injuries, Experimental | 6 | 2013 | 81 | 0.530 |
Why?
| | Gene Expression Regulation, Neoplastic | 10 | 2012 | 855 | 0.530 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.530 |
Why?
| | Organ Sparing Treatments | 3 | 2016 | 57 | 0.520 |
Why?
| | Cell Survival | 26 | 2012 | 600 | 0.520 |
Why?
| | Animals | 52 | 2021 | 13384 | 0.480 |
Why?
| | Pandemics | 1 | 2020 | 584 | 0.480 |
Why?
| | Mammary Neoplasms, Experimental | 3 | 2012 | 122 | 0.470 |
Why?
| | Radiosurgery | 2 | 2016 | 131 | 0.450 |
Why?
| | Organs at Risk | 3 | 2016 | 75 | 0.420 |
Why?
| | Head and Neck Neoplasms | 3 | 2017 | 288 | 0.420 |
Why?
| | Radiotherapy Dosage | 13 | 2017 | 255 | 0.400 |
Why?
| | Peptides | 3 | 2012 | 222 | 0.400 |
Why?
| | Radiation Injuries | 3 | 2013 | 110 | 0.400 |
Why?
| | Ultrasonic Therapy | 5 | 2008 | 30 | 0.390 |
Why?
| | Galectin 1 | 1 | 2012 | 20 | 0.380 |
Why?
| | HSP70 Heat-Shock Proteins | 5 | 2001 | 61 | 0.380 |
Why?
| | Blood Vessels | 1 | 2012 | 66 | 0.380 |
Why?
| | Brain Neoplasms | 2 | 2012 | 289 | 0.360 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 133 | 0.360 |
Why?
| | Tumor Cells, Cultured | 21 | 2001 | 456 | 0.340 |
Why?
| | Bone and Bones | 2 | 2011 | 494 | 0.340 |
Why?
| | Myocardium | 4 | 2014 | 453 | 0.340 |
Why?
| | Acetylcysteine | 2 | 2010 | 102 | 0.330 |
Why?
| | Mice | 16 | 2021 | 5875 | 0.330 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2012 | 332 | 0.330 |
Why?
| | Prostatic Neoplasms | 6 | 2017 | 399 | 0.330 |
Why?
| | Fibroblast Growth Factor 2 | 3 | 1999 | 34 | 0.320 |
Why?
| | Nuclear Proteins | 4 | 1996 | 245 | 0.310 |
Why?
| | Bone Density | 1 | 2011 | 399 | 0.310 |
Why?
| | Cranial Irradiation | 2 | 2009 | 18 | 0.310 |
Why?
| | Cerebellar Neoplasms | 2 | 2009 | 21 | 0.310 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2017 | 247 | 0.310 |
Why?
| | Combined Modality Therapy | 10 | 2012 | 636 | 0.300 |
Why?
| | Heat-Shock Response | 2 | 2005 | 27 | 0.290 |
Why?
| | Medulloblastoma | 1 | 2008 | 18 | 0.290 |
Why?
| | Oxygen Consumption | 1 | 2009 | 198 | 0.290 |
Why?
| | Isoquinolines | 4 | 1996 | 24 | 0.280 |
Why?
| | Humans | 58 | 2021 | 52205 | 0.270 |
Why?
| | Cricetinae | 17 | 2021 | 194 | 0.270 |
Why?
| | Whole-Body Irradiation | 3 | 2020 | 127 | 0.270 |
Why?
| | Piperazines | 4 | 1996 | 117 | 0.260 |
Why?
| | Cell Hypoxia | 2 | 2012 | 83 | 0.250 |
Why?
| | Radiobiology | 1 | 2005 | 21 | 0.250 |
Why?
| | Medicine | 1 | 2005 | 53 | 0.240 |
Why?
| | Rats | 17 | 2021 | 3186 | 0.230 |
Why?
| | Cell Nucleus | 5 | 1996 | 187 | 0.230 |
Why?
| | Radiation Dosage | 7 | 2008 | 161 | 0.230 |
Why?
| | Dose-Response Relationship, Radiation | 8 | 2012 | 182 | 0.230 |
Why?
| | Breast Neoplasms | 8 | 2016 | 1200 | 0.230 |
Why?
| | Cycloheximide | 8 | 1994 | 35 | 0.220 |
Why?
| | Sulfonamides | 2 | 1995 | 133 | 0.220 |
Why?
| | Brain | 1 | 2012 | 1322 | 0.220 |
Why?
| | Brachytherapy | 7 | 1998 | 48 | 0.210 |
Why?
| | Tocotrienols | 2 | 2013 | 37 | 0.200 |
Why?
| | Radiotherapy, Conformal | 2 | 2016 | 53 | 0.200 |
Why?
| | Radiation Tolerance | 7 | 2013 | 84 | 0.200 |
Why?
| | Neovascularization, Pathologic | 3 | 2012 | 151 | 0.200 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2000 | 155 | 0.200 |
Why?
| | Transcription Factor AP-1 | 3 | 1999 | 61 | 0.190 |
Why?
| | Paclitaxel | 2 | 2009 | 89 | 0.190 |
Why?
| | Promoter Regions, Genetic | 4 | 2001 | 467 | 0.190 |
Why?
| | Drug Resistance, Multiple | 6 | 2000 | 24 | 0.180 |
Why?
| | Sodium Compounds | 3 | 1994 | 10 | 0.180 |
Why?
| | Arsenites | 3 | 1994 | 12 | 0.180 |
Why?
| | Signal Transduction | 4 | 2013 | 1669 | 0.180 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.180 |
Why?
| | Arsenic | 2 | 1991 | 22 | 0.170 |
Why?
| | Lung Neoplasms | 3 | 2017 | 636 | 0.170 |
Why?
| | Time Factors | 13 | 2014 | 2948 | 0.170 |
Why?
| | Angiogenesis Inhibitors | 2 | 2012 | 183 | 0.160 |
Why?
| | Models, Biological | 3 | 2016 | 731 | 0.160 |
Why?
| | Cell Line | 11 | 2005 | 1022 | 0.160 |
Why?
| | Crystallins | 2 | 1996 | 11 | 0.160 |
Why?
| | Carcinoma | 4 | 1999 | 137 | 0.150 |
Why?
| | Glucose | 3 | 2000 | 355 | 0.150 |
Why?
| | CHO Cells | 7 | 1996 | 125 | 0.150 |
Why?
| | Male | 22 | 2021 | 26656 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 1161 | 0.140 |
Why?
| | Adenoviridae | 4 | 2001 | 46 | 0.140 |
Why?
| | Temperature | 7 | 2005 | 165 | 0.140 |
Why?
| | Proteins | 3 | 2010 | 347 | 0.140 |
Why?
| | MicroRNAs | 1 | 2021 | 385 | 0.140 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2010 | 52 | 0.140 |
Why?
| | Genes, bcl-2 | 1 | 1997 | 9 | 0.140 |
Why?
| | Enzyme Inhibitors | 3 | 1996 | 371 | 0.140 |
Why?
| | Rectum | 4 | 1998 | 55 | 0.130 |
Why?
| | Genes, myc | 1 | 1997 | 39 | 0.130 |
Why?
| | Esophageal Neoplasms | 1 | 1998 | 111 | 0.130 |
Why?
| | Protein Kinase C | 5 | 1996 | 68 | 0.130 |
Why?
| | Radiation Protection | 2 | 2016 | 47 | 0.130 |
Why?
| | Cell Line, Tumor | 4 | 2012 | 1427 | 0.120 |
Why?
| | DNA-Binding Proteins | 3 | 1996 | 422 | 0.120 |
Why?
| | Base Sequence | 7 | 2009 | 640 | 0.120 |
Why?
| | Mice, Inbred C57BL | 2 | 2011 | 1880 | 0.120 |
Why?
| | Molecular Sequence Data | 7 | 2009 | 778 | 0.120 |
Why?
| | Fourier Analysis | 1 | 1995 | 18 | 0.120 |
Why?
| | Transcription, Genetic | 4 | 1999 | 378 | 0.120 |
Why?
| | Craniospinal Irradiation | 1 | 2014 | 9 | 0.120 |
Why?
| | Neoplasm Proteins | 2 | 1997 | 333 | 0.120 |
Why?
| | Genetic Therapy | 3 | 2001 | 119 | 0.110 |
Why?
| | Phosphorylation | 5 | 2013 | 527 | 0.110 |
Why?
| | Radiation Pneumonitis | 2 | 2016 | 11 | 0.110 |
Why?
| | Equipment Design | 2 | 2012 | 284 | 0.110 |
Why?
| | Apoptosis | 2 | 2014 | 1114 | 0.110 |
Why?
| | Harringtonines | 1 | 1993 | 3 | 0.110 |
Why?
| | Phantoms, Imaging | 3 | 2011 | 119 | 0.110 |
Why?
| | Transcription Factors | 2 | 1996 | 566 | 0.110 |
Why?
| | RNA, Messenger | 5 | 1999 | 1131 | 0.110 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 170 | 0.110 |
Why?
| | Microscopy, Fluorescence | 2 | 2009 | 145 | 0.110 |
Why?
| | Pentoxifylline | 1 | 2013 | 13 | 0.110 |
Why?
| | Immunohistochemistry | 2 | 2013 | 979 | 0.110 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 1993 | 71 | 0.100 |
Why?
| | Female | 27 | 2021 | 28061 | 0.100 |
Why?
| | Monte Carlo Method | 1 | 2013 | 87 | 0.100 |
Why?
| | Radiography | 3 | 2009 | 469 | 0.100 |
Why?
| | Genetic Vectors | 4 | 2001 | 127 | 0.100 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 4 | 1996 | 6 | 0.100 |
Why?
| | Kininogens | 1 | 2012 | 3 | 0.100 |
Why?
| | Kallikrein-Kinin System | 1 | 2012 | 3 | 0.100 |
Why?
| | Ablation Techniques | 1 | 2012 | 19 | 0.100 |
Why?
| | Protein Biosynthesis | 2 | 1996 | 258 | 0.100 |
Why?
| | Deuterium | 1 | 1992 | 46 | 0.100 |
Why?
| | Tumor Burden | 2 | 2010 | 136 | 0.100 |
Why?
| | Cisplatin | 4 | 2009 | 285 | 0.100 |
Why?
| | 3T3 Cells | 4 | 1996 | 58 | 0.100 |
Why?
| | Bystander Effect | 1 | 2012 | 25 | 0.100 |
Why?
| | Computer Simulation | 5 | 2016 | 289 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 4 | 2013 | 50 | 0.100 |
Why?
| | Carrier Proteins | 1 | 1993 | 311 | 0.090 |
Why?
| | Transfection | 5 | 2000 | 357 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2011 | 203 | 0.090 |
Why?
| | Models, Chemical | 2 | 2008 | 66 | 0.090 |
Why?
| | Myocarditis | 1 | 2012 | 49 | 0.090 |
Why?
| | Adaptation, Physiological | 1 | 1992 | 110 | 0.090 |
Why?
| | Acclimatization | 1 | 1991 | 23 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2012 | 182 | 0.090 |
Why?
| | Organ Specificity | 1 | 2011 | 115 | 0.090 |
Why?
| | Colonic Neoplasms | 6 | 1995 | 163 | 0.090 |
Why?
| | Nucleoside Deaminases | 3 | 2001 | 4 | 0.090 |
Why?
| | Thymidine Kinase | 3 | 2001 | 19 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2012 | 1023 | 0.090 |
Why?
| | Gene Expression | 4 | 2012 | 616 | 0.090 |
Why?
| | Blotting, Western | 6 | 2012 | 590 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2010 | 73 | 0.080 |
Why?
| | Mitochondria | 1 | 2014 | 428 | 0.080 |
Why?
| | Malformations of Cortical Development | 1 | 2009 | 4 | 0.080 |
Why?
| | Cytokines | 1 | 1993 | 622 | 0.080 |
Why?
| | Tubulin | 1 | 2009 | 21 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 3 | 1997 | 327 | 0.080 |
Why?
| | Genes, jun | 3 | 1999 | 21 | 0.080 |
Why?
| | Optic Nerve Diseases | 1 | 2009 | 23 | 0.080 |
Why?
| | Genes, fos | 3 | 1999 | 28 | 0.080 |
Why?
| | Taxoids | 1 | 2009 | 37 | 0.080 |
Why?
| | Middle Aged | 9 | 2021 | 13005 | 0.080 |
Why?
| | Carboplatin | 1 | 2009 | 57 | 0.080 |
Why?
| | Fluorouracil | 1 | 2009 | 59 | 0.080 |
Why?
| | Body Weight | 1 | 2011 | 522 | 0.080 |
Why?
| | Information Systems | 1 | 1989 | 27 | 0.080 |
Why?
| | Bone Marrow | 3 | 2010 | 364 | 0.080 |
Why?
| | Disease Progression | 1 | 2012 | 870 | 0.080 |
Why?
| | Spinal Neoplasms | 1 | 2009 | 29 | 0.080 |
Why?
| | Necrosis | 1 | 2009 | 173 | 0.080 |
Why?
| | Cell Death | 3 | 2005 | 175 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2009 | 2267 | 0.080 |
Why?
| | History, 20th Century | 1 | 2009 | 96 | 0.080 |
Why?
| | Osteogenesis | 1 | 2011 | 366 | 0.080 |
Why?
| | Aged | 6 | 2021 | 10102 | 0.070 |
Why?
| | Carbon | 1 | 2008 | 55 | 0.070 |
Why?
| | Cricetulus | 9 | 1990 | 104 | 0.070 |
Why?
| | Oxidative Stress | 3 | 2012 | 804 | 0.070 |
Why?
| | Weight Loss | 1 | 2010 | 248 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2010 | 422 | 0.070 |
Why?
| | Genes, Recessive | 2 | 2009 | 16 | 0.070 |
Why?
| | Radiotherapy, Computer-Assisted | 1 | 2007 | 16 | 0.070 |
Why?
| | Skull | 1 | 2007 | 80 | 0.070 |
Why?
| | Oligodeoxyribonucleotides | 3 | 1996 | 30 | 0.070 |
Why?
| | Spine | 1 | 2007 | 88 | 0.070 |
Why?
| | Adult | 8 | 2021 | 14128 | 0.070 |
Why?
| | Ovary | 6 | 1990 | 107 | 0.070 |
Why?
| | Central Nervous System Neoplasms | 1 | 2007 | 69 | 0.060 |
Why?
| | Fibrosarcoma | 3 | 2011 | 16 | 0.060 |
Why?
| | Cell Cycle | 3 | 1996 | 230 | 0.060 |
Why?
| | Particle Accelerators | 2 | 2017 | 51 | 0.060 |
Why?
| | Genetic Variation | 2 | 2009 | 230 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 1993 | 1219 | 0.060 |
Why?
| | Flow Cytometry | 3 | 1996 | 401 | 0.060 |
Why?
| | Mitosis | 2 | 1996 | 88 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2014 | 1548 | 0.060 |
Why?
| | DNA Damage | 4 | 2012 | 305 | 0.060 |
Why?
| | Swine | 3 | 2012 | 426 | 0.060 |
Why?
| | DNA Repair | 4 | 1988 | 195 | 0.060 |
Why?
| | Ultrasonics | 2 | 1982 | 26 | 0.060 |
Why?
| | DNA, Neoplasm | 2 | 1993 | 146 | 0.060 |
Why?
| | Antiviral Agents | 3 | 2021 | 177 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2012 | 6571 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2021 | 3388 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2012 | 5405 | 0.060 |
Why?
| | Protein Synthesis Inhibitors | 2 | 1996 | 16 | 0.050 |
Why?
| | Gene Transfer Techniques | 2 | 2001 | 40 | 0.050 |
Why?
| | Cytomegalovirus | 2 | 2001 | 29 | 0.050 |
Why?
| | Diathermy | 1 | 1983 | 1 | 0.050 |
Why?
| | Recombinant Proteins | 3 | 2000 | 483 | 0.050 |
Why?
| | Mutation | 1 | 2009 | 1347 | 0.050 |
Why?
| | Magnetics | 1 | 1983 | 28 | 0.050 |
Why?
| | X-Rays | 4 | 2016 | 55 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1031 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 49 | 0.050 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2000 | 72 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 990 | 0.050 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 2 | 2013 | 39 | 0.050 |
Why?
| | Prodrugs | 2 | 2001 | 35 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2002 | 20 | 0.050 |
Why?
| | Flucytosine | 2 | 1999 | 13 | 0.050 |
Why?
| | Antimetabolites | 2 | 1999 | 12 | 0.050 |
Why?
| | Ganciclovir | 2 | 1999 | 24 | 0.050 |
Why?
| | Genetic Markers | 1 | 2002 | 109 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 877 | 0.050 |
Why?
| | Microcephaly | 1 | 2002 | 41 | 0.050 |
Why?
| | Ferrets | 1 | 2021 | 7 | 0.050 |
Why?
| | Antigens, CD | 2 | 2013 | 218 | 0.050 |
Why?
| | Glycolysis | 1 | 2021 | 73 | 0.040 |
Why?
| | Transgenes | 1 | 2001 | 51 | 0.040 |
Why?
| | Luminescent Proteins | 1 | 2001 | 50 | 0.040 |
Why?
| | ROC Curve | 1 | 2021 | 251 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2001 | 86 | 0.040 |
Why?
| | Green Fluorescent Proteins | 1 | 2001 | 87 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 2 | 1999 | 176 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1999 | 60 | 0.040 |
Why?
| | Algorithms | 2 | 2016 | 667 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 1999 | 75 | 0.040 |
Why?
| | Rabbits | 2 | 2010 | 374 | 0.040 |
Why?
| | Proteomics | 1 | 2021 | 324 | 0.040 |
Why?
| | Linear Models | 2 | 2016 | 286 | 0.040 |
Why?
| | Child, Preschool | 4 | 2009 | 4023 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 1991 | 467 | 0.040 |
Why?
| | Kinetics | 3 | 1996 | 622 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2009 | 1211 | 0.040 |
Why?
| | Protein Kinase C-alpha | 2 | 2013 | 10 | 0.030 |
Why?
| | Rectal Diseases | 1 | 1997 | 11 | 0.030 |
Why?
| | Protein Binding | 2 | 1996 | 666 | 0.030 |
Why?
| | Inflammation | 1 | 2021 | 639 | 0.030 |
Why?
| | Nocodazole | 1 | 1996 | 4 | 0.030 |
Why?
| | Cell Division | 2 | 1996 | 289 | 0.030 |
Why?
| | Colony-Forming Units Assay | 1 | 1996 | 23 | 0.030 |
Why?
| | Glioma | 3 | 1993 | 78 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 34 | 0.030 |
Why?
| | Body Temperature | 2 | 1989 | 77 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 1998 | 179 | 0.030 |
Why?
| | Consanguinity | 2 | 2009 | 18 | 0.030 |
Why?
| | Microtubules | 1 | 1996 | 39 | 0.030 |
Why?
| | DNA | 4 | 1988 | 549 | 0.030 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 1996 | 5 | 0.030 |
Why?
| | Nuclear Envelope | 1 | 1996 | 4 | 0.030 |
Why?
| | Calorimetry, Differential Scanning | 1 | 1996 | 8 | 0.030 |
Why?
| | Detergents | 1 | 1996 | 15 | 0.030 |
Why?
| | Serum Albumin, Bovine | 1 | 1996 | 22 | 0.030 |
Why?
| | Wound Healing | 1 | 1998 | 219 | 0.030 |
Why?
| | Microinjections | 1 | 1996 | 35 | 0.030 |
Why?
| | Isoenzymes | 1 | 1996 | 166 | 0.030 |
Why?
| | Permeability | 1 | 1996 | 66 | 0.030 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2016 | 34 | 0.030 |
Why?
| | Formaldehyde | 1 | 1996 | 51 | 0.030 |
Why?
| | Polymers | 1 | 1996 | 49 | 0.030 |
Why?
| | Poisson Distribution | 1 | 2016 | 36 | 0.030 |
Why?
| | Quality Assurance, Health Care | 3 | 1991 | 149 | 0.030 |
Why?
| | Solubility | 1 | 1996 | 79 | 0.030 |
Why?
| | Cytosine Deaminase | 3 | 2001 | 8 | 0.030 |
Why?
| | Probability | 1 | 2016 | 171 | 0.030 |
Why?
| | G2 Phase | 1 | 1995 | 13 | 0.030 |
Why?
| | Hypoglycemia | 1 | 1996 | 59 | 0.030 |
Why?
| | Multiple Myeloma | 1 | 2010 | 3049 | 0.030 |
Why?
| | Adolescent | 4 | 2009 | 6685 | 0.030 |
Why?
| | Radio Waves | 1 | 1995 | 6 | 0.030 |
Why?
| | Neoplasms, Experimental | 2 | 2009 | 112 | 0.030 |
Why?
| | Mathematics | 1 | 1995 | 40 | 0.030 |
Why?
| | Thermodynamics | 1 | 1995 | 35 | 0.030 |
Why?
| | Radiation, Ionizing | 1 | 1995 | 101 | 0.030 |
Why?
| | Child | 4 | 2009 | 7143 | 0.030 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2014 | 18 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 39 | 0.030 |
Why?
| | Gliosarcoma | 1 | 1994 | 5 | 0.030 |
Why?
| | Cell Respiration | 1 | 2014 | 41 | 0.030 |
Why?
| | HSC70 Heat-Shock Proteins | 1 | 1993 | 7 | 0.030 |
Why?
| | Enzyme Activation | 3 | 2000 | 270 | 0.030 |
Why?
| | bcl-2-Associated X Protein | 1 | 2014 | 58 | 0.030 |
Why?
| | Software | 1 | 2016 | 279 | 0.030 |
Why?
| | Protein Conformation | 1 | 2014 | 176 | 0.030 |
Why?
| | Cell Count | 1 | 2013 | 144 | 0.030 |
Why?
| | Cells, Cultured | 4 | 1991 | 1560 | 0.030 |
Why?
| | Mast Cells | 1 | 2013 | 55 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 129 | 0.030 |
Why?
| | Cell Differentiation | 1 | 1996 | 663 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 1995 | 1373 | 0.030 |
Why?
| | Drug Interactions | 1 | 2013 | 205 | 0.030 |
Why?
| | Skin Temperature | 1 | 2012 | 17 | 0.030 |
Why?
| | Multigene Family | 1 | 1992 | 48 | 0.020 |
Why?
| | Mitochondrial Swelling | 1 | 2012 | 4 | 0.020 |
Why?
| | Rats, Inbred BN | 1 | 2012 | 13 | 0.020 |
Why?
| | Receptor, Bradykinin B2 | 1 | 2012 | 7 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 228 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 168 | 0.020 |
Why?
| | Film Dosimetry | 1 | 2012 | 15 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 454 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 451 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 121 | 0.020 |
Why?
| | Neck | 1 | 2012 | 97 | 0.020 |
Why?
| | Burns | 2 | 2012 | 162 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2013 | 261 | 0.020 |
Why?
| | Computer-Aided Design | 1 | 2011 | 20 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2011 | 43 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2013 | 265 | 0.020 |
Why?
| | Evaluation Studies as Topic | 2 | 1988 | 105 | 0.020 |
Why?
| | Partial Pressure | 1 | 2011 | 14 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 580 | 0.020 |
Why?
| | Carbocyanines | 1 | 1990 | 7 | 0.020 |
Why?
| | Quercetin | 1 | 1990 | 18 | 0.020 |
Why?
| | Molecular Weight | 1 | 1990 | 82 | 0.020 |
Why?
| | Biological Transport | 1 | 1990 | 158 | 0.020 |
Why?
| | Bone Transplantation | 1 | 2010 | 42 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2011 | 184 | 0.020 |
Why?
| | HeLa Cells | 1 | 1990 | 260 | 0.020 |
Why?
| | Pakistan | 1 | 2009 | 20 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 15 | 0.020 |
Why?
| | Protein Transport | 1 | 2010 | 179 | 0.020 |
Why?
| | Pedigree | 1 | 2009 | 125 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2011 | 402 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 122 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2009 | 69 | 0.020 |
Why?
| | Leucine | 1 | 1990 | 114 | 0.020 |
Why?
| | Filing | 1 | 1989 | 1 | 0.020 |
Why?
| | DNA, Single-Stranded | 3 | 1979 | 88 | 0.020 |
Why?
| | Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| | Syndrome | 1 | 2009 | 247 | 0.020 |
Why?
| | Metaphase | 1 | 1968 | 46 | 0.020 |
Why?
| | Phenotype | 2 | 2002 | 787 | 0.020 |
Why?
| | Chromosomes | 1 | 1968 | 30 | 0.020 |
Why?
| | Escherichia coli | 2 | 2001 | 187 | 0.020 |
Why?
| | Metals | 1 | 2008 | 35 | 0.020 |
Why?
| | Acute Disease | 1 | 2009 | 373 | 0.020 |
Why?
| | Glutathione | 2 | 2000 | 305 | 0.020 |
Why?
| | Lung | 1 | 2011 | 500 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1997 | 96 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 503 | 0.020 |
Why?
| | Liver | 2 | 2011 | 1156 | 0.020 |
Why?
| | Survival Rate | 1 | 2009 | 939 | 0.020 |
Why?
| | Kidney | 1 | 2011 | 707 | 0.020 |
Why?
| | Skin | 1 | 2009 | 417 | 0.020 |
Why?
| | Rats, Wistar | 2 | 1997 | 193 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2009 | 1021 | 0.020 |
Why?
| | Electrodes | 1 | 1984 | 35 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 2002 | 42 | 0.010 |
Why?
| | Medical Laboratory Science | 1 | 1982 | 2 | 0.010 |
Why?
| | Crossing Over, Genetic | 1 | 1982 | 8 | 0.010 |
Why?
| | Cystamine | 1 | 1982 | 2 | 0.010 |
Why?
| | Cysteamine | 1 | 1982 | 7 | 0.010 |
Why?
| | Sister Chromatid Exchange | 1 | 1982 | 15 | 0.010 |
Why?
| | Gases | 1 | 1982 | 9 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 1982 | 66 | 0.010 |
Why?
| | Methods | 1 | 1981 | 52 | 0.010 |
Why?
| | Thoracic Neoplasms | 1 | 1981 | 13 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 1981 | 16 | 0.010 |
Why?
| | Pelvic Neoplasms | 1 | 1981 | 13 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1982 | 163 | 0.010 |
Why?
| | Genes, p53 | 1 | 2001 | 52 | 0.010 |
Why?
| | Intellectual Disability | 1 | 2002 | 127 | 0.010 |
Why?
| | Cytarabine | 1 | 1981 | 42 | 0.010 |
Why?
| | Clinical Protocols | 2 | 1991 | 108 | 0.010 |
Why?
| | Mitomycins | 1 | 1980 | 2 | 0.010 |
Why?
| | Dipeptides | 1 | 2000 | 21 | 0.010 |
Why?
| | Cysteine | 1 | 2000 | 49 | 0.010 |
Why?
| | Bleomycin | 1 | 1979 | 38 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 1999 | 39 | 0.010 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1999 | 49 | 0.010 |
Why?
| | Young Adult | 1 | 2009 | 4313 | 0.010 |
Why?
| | Doxorubicin | 1 | 2000 | 238 | 0.010 |
Why?
| | Herpesvirus 1, Human | 1 | 1998 | 17 | 0.010 |
Why?
| | Glutathione Disulfide | 1 | 1998 | 38 | 0.010 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 1997 | 8 | 0.010 |
Why?
| | Iridium Radioisotopes | 1 | 1997 | 3 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1997 | 85 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2001 | 295 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 1997 | 66 | 0.010 |
Why?
| | Glutamic Acid | 1 | 1998 | 105 | 0.010 |
Why?
| | Mice, Nude | 1 | 1997 | 232 | 0.010 |
Why?
| | S Phase | 1 | 1996 | 19 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1996 | 106 | 0.010 |
Why?
| | Glutamine | 1 | 1998 | 176 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 1997 | 134 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1996 | 135 | 0.010 |
Why?
| | Cytoplasm | 1 | 1996 | 93 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 1980 | 404 | 0.010 |
Why?
| | Intestinal Obstruction | 1 | 1996 | 38 | 0.010 |
Why?
| | Plasmids | 1 | 1996 | 163 | 0.010 |
Why?
| | Diarrhea | 1 | 1996 | 95 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2002 | 2821 | 0.010 |
Why?
| | Sodium Salicylate | 1 | 1994 | 4 | 0.010 |
Why?
| | Cadmium Chloride | 1 | 1994 | 3 | 0.010 |
Why?
| | Physical Stimulation | 1 | 1994 | 29 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1994 | 27 | 0.010 |
Why?
| | Electrons | 1 | 1974 | 21 | 0.010 |
Why?
| | Adaptation, Biological | 1 | 1994 | 11 | 0.010 |
Why?
| | Cadmium | 1 | 1994 | 21 | 0.010 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1994 | 42 | 0.010 |
Why?
| | Chlorides | 1 | 1994 | 43 | 0.010 |
Why?
| | Infant | 1 | 2002 | 3674 | 0.010 |
Why?
| | Stress, Physiological | 1 | 1994 | 183 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1997 | 1469 | 0.010 |
Why?
| | Equipment Safety | 1 | 1991 | 11 | 0.010 |
Why?
| | Documentation | 1 | 1991 | 33 | 0.010 |
Why?
| | Fibroblasts | 1 | 1993 | 354 | 0.010 |
Why?
| | Histidinol | 1 | 1990 | 1 | 0.010 |
Why?
| | Puromycin | 1 | 1990 | 2 | 0.010 |
Why?
| | Electromagnetic Phenomena | 1 | 1988 | 4 | 0.000 |
Why?
| | Drug Synergism | 1 | 1981 | 148 | 0.000 |
Why?
| | Cross-Linking Reagents | 1 | 1980 | 43 | 0.000 |
Why?
| | Remission, Spontaneous | 1 | 1979 | 24 | 0.000 |
Why?
| | Creatine Kinase | 1 | 1979 | 29 | 0.000 |
Why?
| | L-Lactate Dehydrogenase | 1 | 1979 | 71 | 0.000 |
Why?
| | Tachycardia | 1 | 1979 | 28 | 0.000 |
Why?
| | Etoposide | 1 | 1979 | 72 | 0.000 |
Why?
| | Drug Therapy, Combination | 1 | 1980 | 395 | 0.000 |
Why?
| | Peripheral Nervous System Diseases | 1 | 1979 | 59 | 0.000 |
Why?
| | Neoplasm Metastasis | 1 | 1979 | 239 | 0.000 |
Why?
| | Melphalan | 1 | 1979 | 181 | 0.000 |
Why?
| | Electroencephalography | 1 | 1979 | 312 | 0.000 |
Why?
| | Melanoma | 1 | 1979 | 280 | 0.000 |
Why?
| | Relative Biological Effectiveness | 1 | 1974 | 8 | 0.000 |
Why?
| | Centrifugation, Density Gradient | 1 | 1974 | 17 | 0.000 |
Why?
| | Pregnancy | 1 | 1982 | 2669 | 0.000 |
Why?
| | Gamma Rays | 1 | 1974 | 49 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1974 | 178 | 0.000 |
Why?
|
|
Corry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|